Indication
MYD88 Gene Mutation
2 clinical trials
3 products
Product
KT-413Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, PK/PD, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients With Relapsed or Refractory B-cell NHLStatus: , Estimated PCD: 2025-04-01
Clinical trial
Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström MacroglobulinemiaStatus: Active (not recruiting), Estimated PCD: 2022-06-06
Product
IBRUTINIBProduct
Venetoclax